PriceTargets.com logo

NASDAQ:APTX - Aptinyx Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.67
  • Forecasted Upside: 757.84 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$0.54 As of 05/25/2022 05:00 PM ET
▼ -0.02 (-3.55%)

This chart shows the closing price for APTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aptinyx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APTX

Analyst Price Target is $4.67
▲ +757.84% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Aptinyx in the last 3 months. The average price target is $4.67, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 757.84% upside from the last price of $0.54.

This chart shows the closing price for APTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in Aptinyx. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/1/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/1/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
5/30/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
8/28/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/26/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/25/2022

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/18/2022Piper SandlerLower Price TargetOverweight$10.00 ➝ $6.00High
4/21/2022SVB LeerinkLower Price TargetOutperform$10.00 ➝ $4.00Low
4/14/2022HC WainwrightLower Price TargetBuy$8.00 ➝ $2.00Low
4/8/2022BMO Capital MarketsLower Price Target$12.00 ➝ $6.00High
4/8/2022Truist FinancialLower Price TargetBuy$12.00 ➝ $5.00High
4/8/2022Cantor FitzgeraldLower Price TargetOverweight$11.00 ➝ $5.00High
4/7/2022William BlairDowngradeOutperform ➝ Market PerformHigh
12/20/2021SVB LeerinkLower Price TargetOutperform$12.00 ➝ $10.00High
11/15/2021SVB LeerinkReiterated RatingBuyHigh
11/10/2021Cantor FitzgeraldReiterated RatingOverweightHigh
4/9/2021HC WainwrightReiterated RatingBuy$8.00High
1/29/2021JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightMedium
11/19/2020HC WainwrightBoost Price TargetPositive ➝ Buy$7.00 ➝ $8.00High
11/13/2020SVB LeerinkLower Price TargetOutperform$14.00 ➝ $12.00High
10/28/2020Cantor FitzgeraldBoost Price TargetOverweight$9.00 ➝ $12.00High
10/27/2020Piper SandlerInitiated CoverageOverweight$10.00Low
10/21/2020CowenReiterated RatingBuyMedium
10/20/2020SVB LeerinkBoost Price TargetOutperform$12.00 ➝ $14.00Low
10/14/2020JPMorgan Chase & Co.Initiated CoverageNeutralMedium
10/1/2020William BlairReiterated RatingBuyLow
8/14/2020BMO Capital MarketsReiterated RatingBuy$13.00Medium
7/1/2020SunTrust BanksInitiated CoverageBuy$15.00High
6/18/2020HC WainwrightReiterated RatingBuy$7.00High
5/7/2020William BlairInitiated CoverageOutperformMedium
4/29/2020HC WainwrightInitiated CoverageBuy$7.00High
11/14/2019CowenReiterated RatingBuyHigh
9/12/2019WedbushInitiated CoverageOutperform$7.00High
8/13/2019JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
6/20/2019SVB LeerinkInitiated CoverageOutperform ➝ Outperform$12.00High
6/10/2019CowenReiterated RatingBuyHigh
4/30/2019Cantor FitzgeraldReiterated RatingBuyLow
3/22/2019BMO Capital MarketsReiterated RatingOutperformHigh
3/22/2019Cantor FitzgeraldLower Price TargetOverweight ➝ Overweight$18.00 ➝ $12.00High
1/18/2019BMO Capital MarketsLower Price TargetOutperform$18.00Low
1/17/2019SVB LeerinkLower Price TargetOutperform$35.00 ➝ $22.00High
1/17/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$30.00 ➝ $8.00High
1/16/2019Cantor FitzgeraldReiterated RatingBuy$40.00High
12/3/2018Cantor FitzgeraldReiterated RatingBuy$40.00Low
11/14/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$40.00High
7/16/2018SVB LeerinkInitiated CoverageOutperform$35.00Low
7/16/2018CowenInitiated CoverageOutperformHigh
7/16/2018JPMorgan Chase & Co.Initiated CoverageOverweight$30.00Low
7/16/2018BMO Capital MarketsInitiated CoverageOutperform$32.00Low
(Data available from 5/25/2017 forward)

News Sentiment Rating

-0.16 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
10/27/2021
  • 2 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
11/26/2021
  • 3 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
12/26/2021
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
1/25/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 4 very negative mentions
Mentions as of
2/24/2022
  • 2 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2022
  • 3 very positive mentions
  • 13 positive mentions
  • 9 negative mentions
  • 3 very negative mentions
Mentions as of
4/25/2022
  • 0 very positive mentions
  • 11 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
Mentions as of
5/25/2022

Current Sentiment

  • 0 very positive mentions
  • 11 positive mentions
  • 4 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Aptinyx logo
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.
Read More

Today's Range

Now: $0.54
Low: $0.50
High: $0.58

50 Day Range

MA: $1.46
Low: $0.57
High: $3.14

52 Week Range

Now: $0.54
Low: $0.50
High: $4.73

Volume

314,934 shs

Average Volume

351,735 shs

Market Capitalization

$36.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.46

Frequently Asked Questions

What sell-side analysts currently cover shares of Aptinyx?

The following sell-side analysts have issued research reports on Aptinyx in the last year: BMO Capital Markets, Cantor Fitzgerald, HC Wainwright, Piper Sandler, SVB Leerink LLC, Truist Financial Co., William Blair, and Zacks Investment Research.
View the latest analyst ratings for APTX.

What is the current price target for Aptinyx?

0 Wall Street analysts have set twelve-month price targets for Aptinyx in the last year. Their average twelve-month price target is $4.67, suggesting a possible upside of 757.8%.
View the latest price targets for APTX.

What is the current consensus analyst rating for Aptinyx?

Aptinyx currently has 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe APTX will outperform the market and that investors should add to their positions of Aptinyx.
View the latest ratings for APTX.

How do I contact Aptinyx's investor relations team?

Aptinyx's physical mailing address is 909 DAVIS STREET SUITE 600, EVANSTON IL, 60201. The company's listed phone number is (847) 871-0377 and its investor relations email address is [email protected] The official website for Aptinyx is www.aptinyx.com. Learn More about contacing Aptinyx investor relations.